Meet Our Young Investigators
Since its establishment in 2007, LCFA has funded over $4 million dollars in lung cancer research grants in partnership with organizations such as the largest international clinical society focusing on lung cancer, the IASLC (International Association for the Study of Lung Cancer), and Bristol Myers Squibb.
Why does LCFA award lung cancer grants to Young Investigators?
To attract the best and the brightest to the field of lung cancer, LCFA is committed to supporting young investigators with significant lung cancer research grant funding to pursue a long-term project over the course of multiple years. Our objective is to support the research of young investigators who present projects designed to improve the care and treatment of individuals with lung cancer. By funding those researchers in the early years of their career, the intent is to keep them focused on lung cancer throughout their careers.
Why does LCFA partner with other funding organizations?
LCFA pursues funding partnerships with industry and organizations like the International Association for the Study of Lung Cancer in an attempt to maximize the reach and productiveness of our lung cancer research grants.
When the young investigators receive this significant funding, they are able to amass data that attracts further funding for their projects from organizations like the National Institutes of Health. This additional funding helps these projects to go from the bench to the bedside, furthering LCFA’s goal of helping more and more lung cancer patients live with lung cancer as a chronic disease.
Learn more about these amazing Young Investigators
Why are LCFA lung cancer research grants so critical to patients?
”Young Investigator grants encourage passionate early career researchers to build their career studying lung cancer. The magnitude of the problem is so large – we need as many enthusiastic investigators studying lung cancer as possible! Research saves lives. Lung Cancer is the #1 cause of cancer related deaths. We need to improve outcomes for all lung cancer patients with research to advance our treatment strategies.” ~Dr. Christine Lovly, Vanderbilt University